For contralateral breast cancer, the cumulative risk 20 years after breast cancer diagnosis was 40% (95% CI, 35%-45%) for BRCA1 and 26% (95% CI, 20%-33%) for BRCA2 carriers (hazard ratio [HR] for comparing BRCA2 vs BRCA1, 0.62; 95% CI, 0.47-0.82; P=.001 for difference). Breast cancer risk increased with increasing number of first- and second-degree relatives diagnosed as having breast cancer for both BRCA1 (HR for ≥2 vs 0 affected relatives, 1.99; 95% CI, 1.41-2.82; P<.001 for trend) and BRCA2 carriers (HR, 1.91; 95% CI, 1.08-3.37; P=.02 for trend)
Germline BRCA mutation and outcome in young-onset BC: a prospective cohort study
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA Mutation Carriers
MINDACT Trial:up to 3 Positive Lymph Node Disease May Avoid Chemotherapy
for ,95% ,cancer ,ci ,breast ,brca1 ,95% ci ,breast cancer ,hr for ,82 p ,of first
درباره این سایت